Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

Search/

Search/

Loading…

Director sold ~$302K of KRYS shares in the open market | OQRO

Home
Insider trades
Krystal Biotech
Director sold ~$302K of KRYS shares in the open market

Insider trade

Director sold ~$302K of KRYS shares in the open market

Traded Sep 4, 2026 · Filed Sep 4, 2026

KRYKrystal BiotechKRYS

~$302K
Approx. value · 826 sh @ $365.41: 1.3M
Holds after · shares reported: −6.5%
stock since the trade · S&P 500 +0.6%, $358.24 → $334.85 on Oct 5

Why it stands out

A Krystal Biotech director sold $302K of Krystal Biotech shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 4, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 4, 2026

Director$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$301,832

Shares × reported transaction price

Timing vs results

32 days after results of Aug 3, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Planned / mechanical clue

Filing box checked: sold under a Rule 10b5-1 plan

Only flagged when a footnote says so; never inferred

After it was reported

After	Stock	S&P 500	Difference
7 days	−4.2%	−1.1%	−3.0%

Past results only. Not a forecast.

Source receipt

Record ID: 0001298711-26-000009
Filed / recorded: Sep 4, 2026, 11:15 PM UTC
Added to OQRO: Oct 6, 2026, 7:59 PM UTC
Parser: form4-xml-v2
Data quality: Verified: identifiers matched exactly
Issuer: Krystal Biotech, Inc.
Issuer CIK: 1711279
Ticker: KRYS
Reporting person: Suma Krishnan
Relationship: Director, Officer, 10% owner
Officer title: President, R&D
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Sep 4, 2026
Transaction code: S
Shares / units: 826
Price per share: $365.41
Acquired / disposed: Disposed (D)
Shares owned after: 1,302,544
Ownership form: Direct
Amendment: No

Footnotes from the filing

The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Around the same time

Dino A RossiDirector

Filed 3w ago

1,187Derivative units

Traded Sep 14 · filed 3 days later

Compensation award — excluded from discretionary-purchase analysis.

More Official record

Dino A RossiDirector

Filed 3w ago

471Derivative units

Traded Sep 14 · filed 3 days later

Compensation award — excluded from discretionary-purchase analysis.

More Official record

Everett Rand SutherlandDirector

Filed 3w ago

1,187Derivative units

Traded Sep 14 · filed 3 days later

Compensation award — excluded from discretionary-purchase analysis.

More Official record